Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label access study of sildenafil (Revatio) for pulmonary arterial hypertension patients in India after completion of study A1481156
2015-002238-37Phase 3
- Sponsor
- Pfizer
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sildenafil in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Primary endpoint: Number of Subjects With Clinical Benefit on Usage of Continued Sildenafil Citrate.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2015-002238-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002238-37.